1. Pink Sheet
  2. >>Market Access

Leqembi Label Recommends Alzheimer’s Patient Registry: A Nod To Medicare Evidence Demands?

 
• By Cathy Kelly

FDA-approved language recommending ongoing patient monitoring through a registry is unusual but not unprecedented to address potential safety concerns.

Registries Face Challenges Recruiting Diverse Set Of Patients • Source: Shutterstock

Labeling for Eisai Co., Ltd./Biogen, Inc.’s new Alzheimer’s drug Leqembi (lecanemab) encourages patient enrollment in the Alzheimer’s Association’s recently launched patient registry, known as Alz-Net, which could provide a framework for collecting the kind of evidence on a voluntary basis that Medicare is mandating in its coverage policy for Alzheimer’s drugs.

Leqembi was approved by the US Food and Drug Administration on 6 January using the agency’s accelerated pathway. It is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.